Delving into the Latest Updates on Guangzhou Innocare Pharma Tech Co Ltd with Synapse

Overview

Tags

Congenital Disorders

Immune System Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

TYK2(Tyrosine-protein kinase 2)	1

1.评估ICP-332治疗中重度特应性皮炎（AD）成人受试者的安全性和耐受性。 2.使用湿疹面积和严重程度指数（EASI）评分，评估ICP-332治疗中重度AD的疗效。 3.ICP-332 治疗中重度AD成人受试者其他疗效终点和患者报告的结果。 4.评估ICP-332 在中重度AD成人受试者中的药代动力学（PK）特征。

[Translation]

1. Evaluate the safety and tolerability of ICP-332 in the treatment of adult subjects with moderate to severe atopic dermatitis (AD). 2. Evaluate the efficacy of ICP-332 in the treatment of moderate to severe AD using the Eczema Area and Severity Index (EASI) score. 3. Other efficacy endpoints and patient-reported outcomes of ICP-332 in the treatment of adult subjects with moderate to severe AD. 4. Evaluate the pharmacokinetic (PK) characteristics of ICP-332 in adult subjects with moderate to severe AD.

Start Date06 Mar 2023

Sponsor / Collaborator

Guangzhou Innocare Pharma Tech Co Ltd

CTR20211781 / CompletedPhase 1

一项评价ICP-332 在健康受试者中安全性、耐受性、药代动力学和药效动力学的单剂量和多剂量递增的随机、双盲、安慰剂对照Ⅰ期临床试验

[Translation] A randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ICP-332 in healthy subjects with single and multiple ascending doses

主要目的：评估健康受试者口服 ICP-332 后的安全性和耐受性。次要目的：评估 ICP-332 在健康受试者体内的药代动力学（PK）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of ICP-332 after oral administration in healthy subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of ICP-332 in healthy subjects.

Start Date09 Aug 2021

Sponsor / Collaborator

Guangzhou Innocare Pharma Tech Co Ltd

100 Clinical Results associated with Guangzhou Innocare Pharma Tech Co Ltd

Login to view more data

0 Patents (Medical) associated with Guangzhou Innocare Pharma Tech Co Ltd

Login to view more data

100 Deals associated with Guangzhou Innocare Pharma Tech Co Ltd

Login to view more data

100 Translational Medicine associated with Guangzhou Innocare Pharma Tech Co Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data